Outcome of Board Meeting

Date: July 10, 2026 To, To, Corporate Relationship Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor, Plot No. C/2, 25th Floor, Dalal Street, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400001, India Mumbai – 400051, India Scrip Code: 532305 Symbol: INDSWFTLAB Subject : Outcome of meeting of the Board of Directors of Ind-Swift Laboratories Limited (“the Company”) in terms of the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Ma’am, With reference to the captioned subject and in terms of the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time (“SEBI Listing Regulations, 2015”), we wish to inform that the Board of Directors of Ind-Swift Laboratories Limited (“the Company”), at their meeting held today, i.e. Friday, July 10, 2026, has inter alia, transacted the following business: 1. Issue and allotment of up to 70,00,000 (Seventy Lakh) Fully Convertible Warrants (“Warrants”), each carrying a right exercisable by the Warrant holder to subscribe to one Equity Share of face value of Rs. 10/- (Rupees Ten Only), to an entity belonging to the “Promoter & Promoter Group”, on a preferential basis, at an issue price of Rs. 196/- (Rupees One Hundred and Ninety-Six only) per Warrant, determined in accordance with the provisions of Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and applicable provisions of Companies Act, 2013 and rules made thereunder, aggregating up to Rs. 1,37,20,00,000/- (Rupees One Hundred Thirty-Seven Crore and Twenty Lakh only), for cash, subject to the approval of the members of the Company and applicable regulatory authorities. The name of the proposed allottee is mentioned below: S. Name of the Proposed Category of Proposed No. of Warrants (Up No. Allottee Allottee to) 1. Essix Biosciences Limited Promoter & Promoter Group 70,00,000 Total 70,00,000 Details as per Regulation 30 of the SEBI Listing Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, with respect to this Preferential Issue is enclosed as Annexure A. 2. Authorized the Preferential Issue Committee of the Board of Directors of the Company to take all necessary actions in connection with this Issue and to finalize/approve all the relevant documents, as may be deemed necessary. 3. Alteration in the Article of Association (AOA) by substituting the existing Article Number 76 by new Article 76, subject to the approval of shareholders at the ensuing Extra Ordinary General Meeting. Details as per Regulation 30 of the SEBI Listing Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, with respect to alteration in the AOA is enclosed as Annexure B. 4. Considered and approved the notice convening the Extra-Ordinary General Meeting (“EGM”) of the Members of the Company scheduled to be held on Wednesday, August 05, 2026, for the purpose of obtaining approval in respect of the proposed Preferential Issue. 5. Appointment of CS Vishal Arora, Practicing Company Secretary, as Scrutinizer to scrutinize the e- voting process in a fair and transparent manner in connection with the Extra Ordinary General Meeting. The meeting of the Board of Directors commenced at 04:00 P.M. and concluded at 05:00 P.M. You are requested to kindly take the same on your records. Thanking You, For Ind-Swift Laboratories Limited Pardeep Verma VP-Corporate Affairs and Company Secretary Annexure A S. No. Particulars Disclosures 1. Type of securities proposed to be Fully Convertible Warrants (“Warrants”) issued 2. Type of issuance Preferential Issue 3. Total number of securities proposed Preferential Issue of up to 70,00,000 (Seventy Lakh) to be issued or total amount for which Fully Convertible Warrants of face value of Rs. 10/- the securities will be issued each, aggregating up to Rs. 1,37,20,00,000/-, for cash, at an issue price of Rs. 196/- per Warrant, determined in accordance with provisions of Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and applicable provisions of Companies Act, 2013. 4. Name and number of the Investor(s) Sr. No. Name of the Proposed Allottee 1. Essix Biosciences Limited 5. Issue price Rs. 196/- per Warrant. 6. In case of convertibles, Intimation on Up to 70,00,000 fully convertible Warrants, convertible conversion of securities or on lapse of into an equivalent number of Equity Shares of face value the tenure of the instrument. of Rs. 10/- each within a maximum period of 18 (Eighteen) months from the date of allotment of such Warrants. 7. Nature of Consideration (Whether Cash cash or consideration other than cash) 8. Any cancellation or termination of Not Applicable proposal for issuance of securities including reasons thereof. Annexure B S. No. Particulars Disclosures 1. Amendment/Substitution in existing Article 76 of the Article of Association shall be AOA substituted as under: The retirement of Directors by rotation and the eligibility for re-appointment shall be governed by the provisions of the Companies Act, 2013 and the rules made thereunder, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, where applicable, and other applicable laws, each as amended, modified, re-enacted o r replaced from time to time.